ArticleBMC microbiology2019
Paromomycin production from Streptomyces rimosus NRRL 2455: statistical optimization and new synergistic antibiotic combinations against multidrug resistant pathogens.
Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Genomic insights and biosynthetic gene cluster analysis ofMicrobiology spectrum · 2026Article
- Solid-state fermentation of pristinamycin by Streptomyces pristinaespiralis NRRL ISP-5338 using D-optimal design.Bioprocess and biosystems engineering · 2025Article
- Therapeutic Potential of Salvianolic Acid B Produced by Streptomyces sp. M4 Against Multi-drug-Resistant Human Pathogens.Current microbiology · 2025Article
- D-optimal design model and biosynthetic pathway for gentamicin production by Micromonospora purpureochromogenes NRRL B-16094.BMC microbiology · 2025Article
- In vitro and preclinical evaluation of the antifungal activity of 6-methoxy-1 H-indole-2-carboxylic acid produced by Bacillus toyonensis strain OQ071612 formulated as nanosponge hydrogel.Microbial cell factories · 2025Article
- Optimization and characterization of bioactive secondary metabolites from Streptomyces sp CMSTAAHL-4 isolated from mangrove sediment.BMC microbiology · 2025Article
- Deciphering the nature and statistical optimization of antimicrobial metabolites of two endophytic bacilli.AMB Express · 2025Article
- Response Surface D-Optimal Design for Optimizing Fortimicins Production by Micromonospora olivasterospora and New Synergistic Fortimicin-A-Antibiotic Combinations.Current microbiology · 2025Article
- Biologically active metabolites ofFuture science OA · 2024Review
- Nanosponge hydrogel of octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl) propanoate of Alcaligenes faecalis.Applied microbiology and biotechnology · 2024Article
- Combinatorial biosynthesis of novel aminoglycoside antibiotics via pathway engineering.AMB Express · 2024Review
- Central composite design for optimizing istamycin production by Streptomyces tenjimariensis.World journal of microbiology & biotechnology · 2024Article
- Evaluation of fortimicin antibiotic combinations against MDR Pseudomonas aeruginosa and resistome analysis of a whole genome sequenced pan-drug resistant isolate.BMC microbiology · 2024Article
- Metagenomic nanopore sequencing for exploring the nature of antimicrobial metabolites of Bacillus haynesii.AMB Express · 2024Article
- Green biologically synthesized metal nanoparticles: biological applications, optimizations and future prospects.Future science OA · 2024Review
- Statistical optimization and gamma irradiation on cephalosporin C production by Acremonium chrysogenum W42-I.AMB Express · 2023Article
- Identification, Characterization, and Production Optimization of 6-Methoxy-1H-Indole-2-Carboxylic Acid Antifungal Metabolite Produced byMicroorganisms · 2023Article
- New Insights on Biological Activities, Chemical Compositions, and Classifications of Marine Actinomycetes Antifouling Agents.Microorganisms · 2023Review
- The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children.Microorganisms · 2023Review
- Balancing Trade-Offs Imposed by Growth Media and Mass Spectrometry for Bacterial Exometabolomics.Applied and environmental microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResponse surface methodology (RSM) employing Box-Behnken design was used to optimize the environmental factors for the production of paromomycin, a 2 deoxystreptamine aminocyclitol aminoglycoside antibiotic, (2DOS-ACAGA) from Streptomyces (S.) rimosus NRRL 2455. Emergence of bacterial resistance caught our attention to consider the combination of antimicrobial agents. The effect of paromomycin combination with other antimicrobial agents was tested on some multiple drug resistant isolates. To the best of our knowledge, this is the first report on optimization of paromomycin production from S. rimosus NRRL 2455. A Quadratic model and response surface method were used by choosing three model factors; pH, incubation time and inoculum size. A total of 17 experiments were done and the response of each experiment was recorded. Concerning the effect of combining paromomycin with different antimicrobial agents, it was tested using the checkerboard assay against six multidrug resistant (MDR) pathogens including; Pseudomonas (P.) aeruginosa (2 isolates), Klebsiella (K.) pneumoniae, Escherichia (E.) coli, methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA). Paromomycin was tested in combination with ceftriaxone, ciprofloxacin, ampicillin/sulbactam, azithromycin, clindamycin and doxycycline.
resultsThe optimum conditions for paromomycin production were a pH of 6, an incubation time of 8.5 days and an inoculum size of 5.5% v/v using the optimized media (soybean meal 30 g/L, NH
conclusionRSM using multifactorial design was a helpful and a reliable method for paromomycin production. Paromomycin combination with ceftriaxone, ciprofloxacin, ampicillin/sulbactam, azithromycin, clindamycin or doxycycline showed mostly synergistic effect on certain selected clinically important MDR pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.